Stockscreener 앱 받기
0.9799
5.07%
0.0473
전일 마감가:
$0.9326
열려 있는:
$0.93
하루 거래량:
334.12K
Relative Volume:
1.61
시가총액:
$44.06M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-0.899
EPS:
-1.09
순현금흐름:
$-13.59M
1주 성능:
-1.05%
1개월 성능:
+0.83%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.87
$1.14
1주일 범위
$0.87
$1.14
52주 변동 폭
$0.81
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
IRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
0.9799 | 44.06M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics to Participate in Upcoming Investor Conference in April - The Manila Times
Exclusive Ophthalmology Gene Therapy Updates: Opus Genetics CEO Takes Center Stage at RBC Conference - Stock Titan
Opus Genetics (NASDAQ:IRD) Receives Buy Rating from HC Wainwright - Defense World
Opus Genetics (NASDAQ:IRD) Price Target Cut to $8.00 by Analysts at Jones Trading - Defense World
Opus Genetics price target lowered to $8 from $9 at JonesResearch - TipRanks
H.C. Wainwright maintains $8 target on Opus Genetics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $8 target on Opus Genetics stock - Investing.com India
Opus Genetics Announces Full Year 2024 Financial Results, Provides Corporate Update - VisionMonday.com
Opus Genetics earnings missed by $1.22, revenue fell short of estimates - Investing.com Canada
Opus Leans Lower on Year-End Figures - Baystreet.ca
Opus Genetics Announces Financial Results for Full Year 2024 - TradingView
Ousted founder of drug development company tries to take back the reins - Crain's Detroit Business
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
Pleasing Signs As A Number Of Insiders Buy Opus Genetics Stock - simplywall.st
Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance
Opus Genetics closes $20M offering, issues private placement - Investing.com India
Opus Genetics closes $20M offering, issues private placement By Investing.com - Investing.com South Africa
Opus Genetics founder Mina Sooch files preliminary proxy materials for co board election - MarketScreener
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - The Manila Times
Opus Genetics Prices Public Offering At $0.95/Share, Raising Over $20M - Nasdaq
Opus Genetics announces $21.5 million capital raise - Investing.com
Opus Genetics Prices Public Offering, Private Placement -March 21, 2025 at 09:33 am EDT - MarketScreener
Opus Genetics Announces Presentation on Phentolamine - GlobeNewswire
Opus Genetics announces $21.5 million capital raise By Investing.com - Investing.com Australia
1 Wall Street Analyst Thinks Tesla Will Hit $425. Is it a Buy Around $235? - The Globe and Mail
Opus Genetics, Inc. Announces $20 Million Public Offering and $1.5 Million Private Placement to Fund Clinical Development Initiatives - Nasdaq
Opus Genetics Announces Pricing of Public Offering and - GlobeNewswire
Opus Genetics Secures $21.5M Backing: Perceptive Advisors Leads Gene Therapy Push - Stock Titan
Opus Genetics reports $56.8 million loss for 2024 By Investing.com - Investing.com South Africa
Opus Genetics reports $56.8 million loss for 2024 - Investing.com
Form 424B5 Opus Genetics, Inc. - StreetInsider
Opus Genetics enhances shareholder rights, sues for patent infringement By Investing.com - Investing.com South Africa
Opus Genetics enhances shareholder rights, sues for patent infringement - Investing.com India
Opus Genetics grants stock options to new employees - Investing.com
Opus Genetics Approves Equity Awards for New Employees Under 2021 Inducement Plan - Nasdaq
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Examining the Potential Price Growth of TREX Co., Inc (TREX) - Knox Daily
Opus Genetics Strengthens Team with Strategic Stock Options Package for Key New Hires - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lumen21 Files Trademark Suit Over Rival's 2020 'Lumen' Rebrand - Bloomberg Law
US Space Force Can Proceed With $2.5 Billion Weapons Procurement - Bloomberg Law
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
Disabled Applicant's Open-Book Exam Request Was Lawfully Denied - Bloomberg Law
1 Stock Under $50 with Exciting Potential and 2 to Ignore - The Globe and Mail
Trump Deportation Threats Draw Lawsuit From Cornell Students (1) - Bloomberg Law
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Pre-market Movers: AWH, TSVT, CUTR, SNOA... - RTTNews
Opus Genetics, Inc. Announces Acceptance of Three Abstracts for Presentation at ARVO 2025 Meeting - Nasdaq
Opus Genetics Announces Presentations at Association for - GlobeNewswire
Can Opus Genetics' Eye Disease Treatments Restore Vision? New Clinical Data Emerges - StockTitan
Opus Genetics faces patent challenge from Sandoz By Investing.com - Investing.com Australia
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):